{"entity":{"id":"eortc-26951","kind":"trial","name":"EORTC 26951","aka":[],"tldr":"EORTC 26951, the European twin of RTOG 9402, confirmed that PCV chemotherapy after radiotherapy greatly lengthens survival in 1p/19q co-deleted oligodendrogliomas.","summary":"EORTC 26951 randomised 368 patients with anaplastic oligodendroglioma or oligoastrocytoma to 59.4 Gy radiotherapy with or without six cycles of adjuvant PCV. With a median follow-up of nearly 12 years, overall survival improved with PCV (42.3 versus 30.6 months overall); in 1p/19q co-deleted tumours median survival was not reached with PCV versus 112 months with radiotherapy alone (van den Bent and colleagues, Journal of Clinical Oncology 2013).","status":"positive","asOf":"2026-09-17","links":[{"label":"JCO 2013","url":"https://doi.org/10.1200/JCO.2012.43.2229"}],"tags":["radiation-wave4"],"related":[],"cancers":["glioblastoma","brain-tumours","oligodendroglioma"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["lomustine","vincristine","procarbazine"],"companies":["curie-nki-eortc"],"institutions":[],"pathways":[],"terms":["chemoradiation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"phase":"3","setting":"Anaplastic oligodendroglial tumours: radiotherapy followed by six cycles of PCV chemotherapy versus radiotherapy alone","sponsor":"EORTC","result":"Median overall survival 42.3 vs 30.6 months overall; in 1p/19q co-deleted tumours not reached vs 112 months.","yearReported":2013,"enrolled":368,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall survival","primary":true,"unit":"months","arms":[{"name":"Radiotherapy + adjuvant PCV","value":42.3},{"name":"Radiotherapy alone","value":30.6}],"hr":0.75,"ci":[0.6,0.95],"source":"https://doi.org/10.1200/JCO.2012.43.2229"},{"endpoint":"Overall survival, 1p/19q co-deleted (80 patients)","unit":"months","arms":[{"name":"Radiotherapy + adjuvant PCV","note":"Not reached"},{"name":"Radiotherapy alone","value":112}],"hr":0.56,"ci":[0.31,1.03],"source":"https://doi.org/10.1200/JCO.2012.43.2229"}]},"route":"/trials/eortc-26951/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"oligodendroglioma","kind":"cancer","name":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","route":"/cancers/oligodendroglioma/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"lomustine","kind":"drug","name":"Lomustine (CCNU)","route":"/drugs/lomustine/"},{"id":"procarbazine","kind":"drug","name":"Procarbazine","route":"/drugs/procarbazine/"},{"id":"vincristine","kind":"drug","name":"Vincristine","route":"/drugs/vincristine/"}],"company":[{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"}],"term":[{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"}],"paper":[{"id":"paper-eortc-26951-van-den-bent-jco-2013","kind":"paper","name":"EORTC 26951: adjuvant PCV after radiotherapy for anaplastic oligodendroglial tumours, long-term follow-up","route":"/key-papers/paper-eortc-26951-van-den-bent-jco-2013/"}]}}